Jun 22, 2026 · 6 min
AbbVie targets Apogee in eleven billion dollar deal as Regenxbio advances
Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline
Major pharmaceutical acquisitions and shifting regulatory pathways are rapidly redefining valuations in the biotechnology sector.
- 1AbbVie is acquiring Apogee Therapeutics for nearly eleven billion dollars to expand its inflammatory disease pipeline.
- 2Regenxbio secured FDA alignment on an accelerated approval pathway for its experimental gene therapy Navsunli.
- 3SpaceX shares experienced a decline following the company's record-breaking initial public offering.
Don't miss
The discussion of AbbVie's massive ten point nine billion dollar acquisition of Apogee Therapeutics to dominate the immunological drug space.
The brief
Biotech deals and regulatory shifts are driving major pre-market action, led by AbbVie's massive move to acquire Apogee Therapeutics to bolster its pipeline in inflammatory disease treatments.
The planned 10.9 billion dollar acquisition highlights the premium pharmaceutical giants are willing to pay for clinical-stage immunological drug developers to secure future growth.
Simultaneously, Regenxbio is gaining strong regulatory momentum after aligning with the FDA on an accelerated approval pathway for its experimental gene therapy, Navsunli.
The pre-market optimism in biotech stands in contrast to private market movements, as SpaceX shares experienced a decline following its record-breaking initial public offering.
What was said on this episode
5 statements · 3 positive · 2 negative
AbbVie is acquiring Apogee Therapeutics for $10.9 billion.
“Abbvie is buying apogee for $10.9 billion”
Listen at 0:53
Apogee has a promising experimental psoriasis compound.
“that company's got a promising experimental compound for psoriasis”
Listen at 1:18
Apogee’s psoriasis compound could rival Sanofi’s Dupixent.
“it could be a rival to France's Sanofi and its blockbuster Dupixit”
Listen at 1:25
Placebo trials are impractical for rare-disease treatments with very few annual patients.
“that's not practical when you're talking about experimental treatments for patients that might only be a few dozen a year”
Listen at 2:37
SpaceX’s bond sale will likely begin massive borrowing to finance its AI ambitions.
“this is likely to be the start of a massive borrowing spree to finance Elon Musk's AI ambitions for the Rocket company”
Listen at 3:59
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Apogee Therapeutics
Food and Drug AdministrationListen to the full episode and explore every guest, topic, and moment on PodLume.